Tesamorelin (development code TH9507) is a synthetic 44-residue analogue of human growth hormone-releasing factor (GRF, also GHRH). PubChem lists it as N-[(3E)-hex-3-enoyl] somatoliberin: the full 1-44 sequence of human GRF with a trans-3-hexenoyl group on the N-terminal tyrosine. It has been characterised in pharmacokinetic studies in dogs, in in vitro metabolism and anti-doping detection work, and in registered clinical trials, which are described here by design and primary endpoint only.